|
**Overview**: Galactosemia 2 Panel**Introduction**: The Galactosemia 2 Panel is a diagnostic tool designed for extended galactosemia screening using whole blood samples. In India, extended screening for GALT, GALE, GALK1 mutations plus enzyme activity helps identify classical and Duarte variants, crucial in neonates with jaundice or sepsis. High morbidity from underdiagnosis in rural/low-SES settings, limited multi-gene testing, delayed diet change leading to liver failure or cataracts. Per molecular pathology practices aligned with ICMR guidelines, the test employs PCR for mutations and enzyme activity over 1-2 days with high accuracy, valuable for comprehensive diagnosis. This diagnostic falls under genetic disorder screening and targets symptomatic neonates or carriers, addressing accurate detection to guide lactose-free formula and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise variant identification and reducing complications. Its whole blood-based approach ensures reliable analysis.**Other Names**: Galacto 2 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Extended galactosemia panel; in India, expanding in newborn screening.**Purpose**: The test assesses 4 parameters including GALT mutation to guide extended galactosemia screening, detect variants, inform management.**Test Parameters**: 1. GALT Mutation, 2. GALE Mutation, 3. GALK1 Mutation, 4. Enzyme Activity.**Pretest Condition**: No fasting required; patients should be symptomatic neonates.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for analysis).**Medical History**: Patients should provide details on jaundice, vomiting, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated galactosemia including failure, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR and enzyme assay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or recent milk exposure can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Pathogenic variants/low activity confirm galactosemia, necessitating specialist input.**Specialist Consultation**: Pediatricians or geneticists should be consulted for management.**Additional Supporting Tests**: Galactose-1-phosphate for confirmation.**Test Limitations**: May miss rare variants; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023. |
